I now have comprehensive material from multiple authoritative textbooks. Let me compile the full 15-mark answer.
Receptor Classification, Slow vs. Fast Receptors, and Properties of Receptors
(MBBS First Year - 15 Marks)
1. DEFINITION OF A RECEPTOR
A receptor is a macromolecular protein (on the cell surface, within the cytoplasm, or in the nucleus) that specifically recognizes and binds an endogenous ligand (hormone, neurotransmitter, drug) and transduces that binding into a cellular response. Receptors are distinct from mere carrier proteins or enzymes because binding initiates signal transduction.
2. CLASSIFICATION OF RECEPTORS
Receptors are classified by structure and transduction mechanism into four major types:
TYPE I - Ligand-Gated Ion Channels (Ionotropic Receptors / "Fast" Receptors)
These receptors are directly linked to an ion channel. Ligand binding opens or closes the channel within milliseconds, without any intermediate steps.
Structure: The receptor protein itself forms the ion channel - it is a multimeric protein spanning the membrane several times.
Examples:
- Nicotinic acetylcholine receptor (nAChR) - at the neuromuscular junction; opens Na+/K+ channels
- GABA-A receptor - opens Cl- channels (inhibitory)
- Glycine receptor - opens Cl- channels (inhibitory)
- NMDA and AMPA glutamate receptors - opens Na+/K+/Ca2+ channels (excitatory)
- 5-HT3 receptor - opens Na+/K+ channels
Mechanism: Ligand binds → conformational change → ion channel opens directly → change in membrane potential (depolarization or hyperpolarization).
TYPE II - G Protein-Coupled Receptors (GPCRs / Metabotropic Receptors / "Slow" Receptors)
The largest family of cell-surface receptors. Binding activates a heterotrimeric G protein (Gα + Gβγ), which then modulates second messengers and/or ion channels indirectly.
Structure: Single polypeptide with 7 transmembrane (7-TM) domains; also called heptahelical receptors.
Subclasses by G protein family:
| G Protein | Effect | Example Receptor |
|---|
| Gs | Activates adenylyl cyclase → ↑cAMP | β-adrenergic, D1 dopamine |
| Gi | Inhibits adenylyl cyclase → ↓cAMP | M2 muscarinic, α2-adrenergic |
| Gq | Activates phospholipase C-β → ↑IP3/DAG/Ca2+ | M1/M3 muscarinic, α1-adrenergic |
| G12/13 | Activates Rho GEFs | Thrombin receptor |
Examples:
- Muscarinic ACh receptor (mAChR): at cardiac parasympathetic synapse - activates Gi, opens GIRK channels → slows heart rate
- Adrenergic receptors (α and β)
- Dopamine, serotonin (5-HT1, 5-HT2, 5-HT4), opioid receptors
Mechanism: Ligand binds → G protein activated → Gα-GTP dissociates from Gβγ → both subunits modulate effectors (adenylyl cyclase, PLC, ion channels) → second messengers (cAMP, IP3, DAG, Ca2+) produced → cellular response. Onset: seconds to minutes.
(Goodman & Gilman's Pharmacological Basis of Therapeutics; Medical Physiology [Boron & Boulpaep])
TYPE III - Enzyme-Linked (Catalytic) Receptors
These receptors have intrinsic enzymatic activity (usually tyrosine kinase) in their intracellular domain, activated upon ligand binding.
Subtypes:
- Receptor Tyrosine Kinases (RTKs): Insulin receptor, PDGF receptor, EGF receptor, VEGF receptor. Ligand binding causes receptor dimerization and autophosphorylation on tyrosine residues → downstream signaling (SH2-domain proteins, MAP kinase cascade, PI3K/Akt pathway).
- Receptor Serine/Threonine Kinases: TGF-β receptor → activates SMAD proteins.
- Membrane-bound Guanylyl Cyclase: Natriuretic peptide receptor → produces cGMP.
- Cytokine Receptors (JAK-STAT pathway): Receptors for interleukins, growth hormone, prolactin - activate JAK kinases → STAT transcription factors.
Onset: Minutes to hours.
TYPE IV - Nuclear (Intracellular) Receptors
These receptors are located inside the cell (cytoplasm or nucleus) rather than on the membrane. Their ligands must be lipid-soluble to diffuse across the cell membrane.
Ligands: Steroid hormones (glucocorticoids, mineralocorticoids, androgens, estrogens), thyroid hormones (T3/T4), vitamin D, retinoic acid.
Mechanism: Lipophilic ligand diffuses across membrane → binds receptor in cytoplasm or nucleus → receptor-ligand complex acts as transcription factor → binds specific DNA sequences (hormone response elements/HREs) → regulates gene expression → protein synthesis changes.
Onset: Hours to days (gene transcription + translation required).
Structure: All share a conserved DNA-binding domain (zinc-finger motif), a ligand-binding domain, and a transactivation domain. The superfamily contains at least 48 genes.
(Medical Physiology [Boron & Boulpaep]; Goodman & Gilman's)
3. FAST vs. SLOW RECEPTORS - A DETAILED COMPARISON
This distinction is central to first-year pharmacology and physiology:
| Feature | Fast Receptors (Ionotropic) | Slow Receptors (Metabotropic/GPCRs) |
|---|
| Structural type | Ligand-gated ion channel (multimeric) | 7-TM GPCR (single polypeptide) |
| Transduction | Direct: ligand opens channel | Indirect: via G protein + second messengers |
| Onset of response | Milliseconds (1-10 ms) | Seconds to minutes |
| Duration of response | Brief (ms range) | Prolonged (seconds-minutes) |
| Second messengers | None required | cAMP, cGMP, IP3, DAG, Ca2+ |
| Effect | Change in membrane potential (depolarization or hyperpolarization) | Diverse: altered enzyme activity, gene expression, ion channel gating |
| Amplification | Low (1:1 or small) | High (one receptor activates thousands of second-messenger molecules) |
| Reversal | On ligand dissociation | Slower - requires GTPase activity (Gα) + phosphodiesterase action |
| Example (ACh system) | Nicotinic AChR at NMJ: Na+/K+ influx → depolarization → muscle contraction | Muscarinic M2 AChR at heart: activates Gi → GIRK channels open → hyperpolarization → ↓HR |
| Example (GABA system) | GABA-A: Cl- influx → fast inhibition | GABA-B: Gi-coupled → K+ channel opening → slow inhibition |
| Pharmacological use | Neuromuscular blockers act here (tubocurarine, succinylcholine) | Beta-blockers, antimuscarinics, opioids act here |
Classic Example to Remember: Both nicotinic and muscarinic receptors respond to acetylcholine but produce completely opposite effects on different tissues - the former is fast (milliseconds), the latter is slow (seconds) - explaining why ACh can both activate skeletal muscle AND slow the heart.
(Medical Physiology; Eric Kandel Principles of Neural Science 6th Edition; Katzung's Basic and Clinical Pharmacology 16th Edition)
4. PROPERTIES OF RECEPTORS
(a) Specificity
Receptors are highly specific for their ligand due to the complementary 3D structure (lock-and-key or induced-fit). A receptor binds only ligands with the correct molecular geometry. E.g., the muscarinic receptor binds muscarine and ACh but not nicotine.
(b) Affinity (Kd)
Affinity is the strength of binding between receptor and ligand, expressed as the dissociation constant (Kd) - the concentration of ligand that occupies 50% of receptors at equilibrium. A lower Kd = higher affinity. Affinity is measured using radioligand-binding assays and Scatchard plots.
(c) Saturability
Receptors are present in finite numbers. As ligand concentration increases, a maximum response is reached when all receptors are occupied - the response cannot be increased beyond this point regardless of further ligand addition.
(d) Reversibility
Receptor-ligand binding is generally reversible (non-covalent: ionic bonds, hydrogen bonds, van der Waals forces). Irreversible binding (covalent) occurs with certain drugs (e.g., organophosphates at acetylcholinesterase; aspirin at COX).
(e) Transduction (Signal Coupling)
The receptor must be coupled to an effector mechanism. Uncoupled receptors (due to mutations or disease) lose the ability to produce a response even when occupied.
(f) Desensitization (Tachyphylaxis)
Repeated or prolonged receptor stimulation leads to reduced response. Mechanisms include:
- Receptor phosphorylation by GRKs (G protein-coupled receptor kinases) → β-arrestin binding → receptor uncoupling
- Internalization (down-regulation): Receptor is removed from the cell surface via endocytosis → fewer surface receptors → diminished response
- Receptor degradation in lysosomes
(g) Up-regulation and Supersensitivity
Prolonged blockade or absence of agonist leads to an increase in receptor number (up-regulation) and heightened sensitivity. Clinically important: abrupt discontinuation of beta-blockers can precipitate rebound hypertension/angina due to up-regulated β-receptors.
(h) Spare Receptors (Receptor Reserve)
Many tissues have more receptors than required for a maximal response. The maximum effect can be achieved at submaximal receptor occupancy. This provides a safety margin and also explains why partial agonists may be full agonists in tissues with large receptor reserve.
(i) Selectivity
Some drugs act on one receptor subtype more than others - e.g., salbutamol is selective for β2 over β1 receptors. Selectivity differs from specificity (specificity = one receptor type; selectivity = preference within a family).
(j) Stereoselectivity
Receptors typically bind one optical isomer (enantiomer) far better than the other. E.g., L-norepinephrine is much more potent than D-norepinephrine at adrenergic receptors.
5. SUMMARY TABLE
| Receptor Class | Location | Mechanism | Speed | Example |
|---|
| Ionotropic (Type I) | Cell membrane | Ion channel | ms (Fast) | nAChR, GABA-A |
| GPCR (Type II) | Cell membrane | G protein → 2nd messenger | Seconds-min (Slow) | mAChR, β-adrenoceptor |
| Enzyme-linked (Type III) | Cell membrane | Intrinsic kinase / JAK | Minutes-hours | Insulin R, EGF R |
| Nuclear (Type IV) | Cytoplasm/Nucleus | Gene transcription | Hours-days | Glucocorticoid R, T3 R |
Key Sources:
- Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th Ed. - Table 3-1 (Classes of Receptors Relevant to Drug Actions)
- Medical Physiology (Boron & Boulpaep) - pp. 51-66, 327-328 (Ionotropic vs. metabotropic receptors)
- Eric Kandel: Principles of Neural Science, 6th Ed. - Fast/slow synaptic transmission
- Katzung's Basic and Clinical Pharmacology, 16th Ed. - GABA-A (fast) vs. GABA-B (slow) receptors